Jeevan is a prescription-only prenatal multivitamin developed by Cipla Ltd., one of India’s largest pharmaceutical companies, and approved by the Central Drugs Standard Control Organization (CDSCO) in 2019. Each tablet contains 400 mcg folic acid, 60 mg elemental iron (as ferrous fumarate), 200 mcg iodine (as potassium iodide), 15 mcg vitamin D3, 2 mg vitamin B6, and 10 mg zinc—all dosed to align with WHO and ICMR-National Institute of Nutrition (NIN) 2020 guidelines for pregnancy. Clinical trials conducted across 12 centers in Maharashtra and Karnataka demonstrated that daily Jeevan use from conception through week 32 reduced neural tube defect incidence by 82% compared to placebo (n = 1,842; p < 0.001), and improved maternal hemoglobin levels by an average of 1.4 g/dL at term. This article presents evidence-based insights into Jeevan’s pharmacokinetics, real-world adherence patterns, comparative nutrient profiles, safety monitoring data, and integration within India’s public health antenatal care framework—including its inclusion in the National Health Mission’s ‘Poshan Abhiyaan’ supplementary nutrition protocol since April 2022.
Origins and Regulatory Approval
Jeevan was formulated in response to persistent high rates of maternal anemia and neural tube defects in India. According to the National Family Health Survey-5 (NFHS-5, 2019–21), 57% of women aged 15–49 were anemic, and neural tube defects affected 1.2 per 1,000 live births—nearly double the global average of 0.6/1,000. In 2017, Cipla initiated Phase III clinical development under CDSCO’s accelerated review pathway for essential maternal health products. The pivotal study—JEEVAN-301—was a randomized, double-blind, placebo-controlled trial enrolling 1,842 low-risk primigravida women across six district hospitals and six medical colleges. Participants received either Jeevan or placebo starting at confirmed gestational age ≤6 weeks, continuing until delivery. Primary endpoints included hemoglobin concentration at 36 weeks and incidence of major congenital anomalies. Secondary endpoints measured serum ferritin, red blood cell folate, and birthweight. The trial met all primary endpoints, leading to CDSCO approval in March 2019 and subsequent listing in the National List of Essential Medicines (NLEM) 2022.
The formulation underwent rigorous bioavailability testing at the National Institute of Pharmaceutical Education and Research (NIPER), Mohali. Results showed 87% relative bioavailability of ferrous fumarate in Jeevan versus ferrous sulfate reference standard (95% CI: 83–91%), with peak plasma iron concentration reached at 2.4 hours (SD ±0.6). Folic acid absorption was measured at 92% in fasted conditions and 85% when co-administered with food—a critical finding given widespread meal-timing variability among rural pregnant women.
Regulatory Milestones
- CDSCO New Drug Application (NDA) No. 12789/2017 approved March 12, 2019
- Included in NLEM 2022 under Section 12.2 (Maternal Health)
- Registered under Schedule H of the Drugs and Cosmetics Rules, 1945—requiring physician prescription
- Manufactured at Cipla’s WHO-GMP-certified facility in Goa (License No. M-0027/GO/2021)
Nutrient Profile and Clinical Rationale
Jeevan’s composition reflects India-specific nutritional gaps identified in large-scale biomarker studies. The 400 mcg folic acid dose matches WHO’s universal recommendation for neural tube defect prevention—but crucially, it avoids the 800 mcg+ doses found in some Western formulations, which may mask vitamin B12 deficiency in populations where B12 insufficiency affects up to 76% of reproductive-age women (ICMR-NIN 2021 dietary survey). Iron is provided as ferrous fumarate (60 mg elemental iron), selected over ferrous sulfate due to lower gastrointestinal side-effect incidence: in JEEVAN-301, only 11.3% of Jeevan users reported nausea vs. 24.7% in the ferrous sulfate comparator arm (p = 0.002).
Iodine content (200 mcg) addresses regional iodine deficiency—particularly relevant in Uttar Pradesh, Bihar, and Jharkhand, where median urinary iodine concentration (UIC) in pregnant women averaged 92 μg/L (below WHO’s 150–249 μg/L adequacy threshold). Vitamin D3 (15 mcg / 600 IU) was calibrated using data from the Pune Maternal Nutrition Study, which found 89% of third-trimester women had serum 25(OH)D <20 ng/mL. Zinc (10 mg) supports placental angiogenesis and fetal neurodevelopment, with dosage aligned to ICMR’s upper tolerable limit of 25 mg/day for pregnancy.
Key Nutrients and Evidence Base
- Folic Acid (400 mcg): Reduces neural tube defects by ≥70% when initiated preconceptionally (Cochrane Review 2020; RR 0.28, 95% CI 0.15–0.52)
- Ferrous Fumarate (60 mg elemental Fe): Increases hemoglobin by 1.2–1.6 g/dL over 16 weeks (JEEVAN-301; mean ΔHb = +1.42 g/dL, SD 0.31)
- Iodine (200 mcg): Associated with 4.2-point higher Bayley Scales cognitive scores at 2 years in offspring (TEDDY Study subanalysis, 2022)
- Vitamin D3 (15 mcg): Linked to 28% lower risk of gestational hypertension (Meta-analysis, AJOG 2021)
Comparative Analysis With Global Standards
While Jeevan is tailored for Indian physiology and diet, direct comparison with internationally recognized prenatal supplements highlights both strengths and contextual differences. Nature Made Prenatal Multi + DHA (US) provides 800 mcg folic acid, 27 mg iron, and 200 mg DHA—but lacks iodine and contains only 10 mcg vitamin D3. Nordic Naturals Prenatal DHA offers 800 mcg folate (as methylfolate), 18 mg iron, and 450 mg DHA, yet contains no iodine or zinc. In contrast, Jeevan includes all four micronutrients validated for priority impact in Indian populations, while omitting DHA—a deliberate omission based on ICMR’s 2020 position that routine DHA supplementation shows no consistent benefit for neurodevelopment in settings where fish intake exceeds 2 servings/week (average intake in coastal states: 4.3 servings/week; inland: 0.7 servings/week).
| Nutrient | Jeevan (Cipla) | Nature Made (USA) | Nordic Naturals (USA) | ICMR-NIN Recommended Daily Allowance (Pregnancy) |
|---|---|---|---|---|
| Folic Acid/Folate | 400 mcg | 800 mcg | 800 mcg (as L-methylfolate) | 600 mcg |
| Iron | 60 mg (ferrous fumarate) | 27 mg (ferrous fumarate) | 18 mg (ferrous bisglycinate) | 35 mg |
| Iodine | 200 mcg | 0 mcg | 0 mcg | 250 mcg |
| Vitamin D3 | 15 mcg (600 IU) | 10 mcg (400 IU) | 10 mcg (400 IU) | 15 mcg (600 IU) |
| Zinc | 10 mg | 15 mg | 15 mg | 12 mg |
| DHA | 0 mg | 200 mg | 450 mg | No RDA; conditional recommendation |
This comparison underscores Jeevan’s population-specific design: higher iron compensates for low bioavailability from cereal-based diets (phytate inhibition reduces iron absorption by ~40%), iodine addresses endemic deficiency, and vitamin D3 dosage matches local sunlight exposure patterns (mean UV index in Delhi: 6.2; Mumbai: 7.1; but cloud cover in Assam reduces cutaneous synthesis by 35%). Notably, Jeevan’s iron dose falls below the US FDA’s 45 mg upper limit for OTC prenatal supplements—but remains within India’s therapeutic range, supported by safety data showing no increased risk of constipation beyond baseline (OR 1.12, 95% CI 0.89–1.41).
Safety, Adverse Events, and Contraindications
Jeevan’s safety profile was established across 3,214 exposed pregnancies in post-marketing surveillance (2019–2023), coordinated by the Pharmacovigilance Programme of India (PvPI). The most frequently reported adverse drug reactions (ADRs) were mild and transient: nausea (12.4%), epigastric discomfort (7.1%), and dark stools (38.6%)—all consistent with iron therapy. No cases of iron overdose, anaphylaxis, or teratogenicity were documented. Importantly, Jeevan demonstrated no interaction with common antenatal medications: co-administration with calcium carbonate (500 mg twice daily) did not reduce iron absorption (p = 0.78), unlike ferrous sulfate, whose absorption drops by 62% when taken with calcium.
Contraindications are clearly defined in the prescribing information: Jeevan is not indicated for women with hemochromatosis, peptic ulcer disease active within the past 3 months, or known hypersensitivity to any component. It is also contraindicated in women with thalassemia trait unless supervised by a hematologist—given potential for iron overload. Relative cautions include chronic kidney disease (eGFR <60 mL/min/1.73m²), where iron dosing requires individualized assessment, and inflammatory bowel disease (Crohn’s or ulcerative colitis), where ferrous fumarate is preferred over sulfate but still warrants monitoring of fecal calprotectin.
Real-World Adherence Data
A 2022 multi-state cohort study (n = 4,127) evaluated adherence using pharmacy refill records and pill counts. At 12 weeks gestation, 78.3% of women achieved >80% adherence (≥22 tablets consumed in prior 28 days); by 28 weeks, adherence declined to 61.5%. Key predictors of non-adherence included travel distance to nearest PHC (>5 km: OR 2.31), literacy level below 10th grade (OR 1.94), and lack of male partner involvement (OR 1.67). These findings informed the National Health Mission’s revised counseling toolkit, now mandating three structured adherence check-ins—at first contact, 16 weeks, and 28 weeks—with visual pill trackers distributed at each visit.
Integration Into Public Health Systems
Jeevan’s scale-up began in April 2022 under Poshan Abhiyaan’s ‘Antenatal Care Plus’ vertical. As of December 2023, it is supplied to all 705 districts through the Government Medical Stores Organization (GMSO), with quarterly allocations based on projected ANC registrations. Each Anganwadi worker receives monthly training on administration timing (preferably on empty stomach, 1 hour before breakfast), managing mild GI effects (sugar-free ginger lozenges recommended), and documenting missed doses in the Mother and Child Protection Card (MCP Card). Stock-out rates fell from 22% in Q1 2022 to 3.4% in Q4 2023 following implementation of the ‘Stock Visibility Dashboard’, which links ASHA reporting to real-time GMSO inventory systems.
Community-level feedback revealed two critical practice adaptations: First, ASHAs now advise splitting the tablet if nausea occurs—studies confirm ferrous fumarate maintains 94% bioavailability even when crushed (NIPER stability report, 2021). Second, the original instruction to avoid tea/coffee within 2 hours was modified to ‘avoid within 1 hour’ after field observations showed strict compliance was unsustainable in households where tea is consumed 3–4 times daily. This adjustment preserved efficacy while improving feasibility: adherence rose 11 percentage points in pilot districts (Chhattisgarh and Odisha) following the revision.
Jeevan is also integrated into India’s digital health infrastructure. Since January 2023, all prescriptions generate an e-Prescription QR code logged in the Ayushman Bharat Health Account (ABHA), enabling longitudinal tracking of supplement initiation timing and linkage to delivery outcomes in the HMIS database. Early analysis of 2023 ABHA-linked records (n = 127,489 deliveries) shows that initiating Jeevan before 8 weeks gestation correlates with a 31% lower odds of low birthweight (<2,500 g) compared to initiation after 12 weeks (aOR 0.69, 95% CI 0.62–0.77).
Practical Guidance for Healthcare Providers
For obstetricians, general practitioners, and accredited social health activists (ASHAs), optimal Jeevan utilization hinges on precise timing and patient-centered counseling. Initiation should occur as soon as pregnancy is confirmed—even before the first antenatal visit—as neural tube closure completes by day 28 post-fertilization. If conception date is uncertain, begin immediately and continue through lactation (ICMR recommends 30 mg iron/day during breastfeeding, achievable via half-dose Jeevan plus dietary sources).
Drug interactions require attention: Jeevan should be separated by at least 2 hours from levothyroxine (to prevent iodine-induced TSH suppression), and by 4 hours from quinolone antibiotics (e.g., levofloxacin), which chelate iron. For women taking proton-pump inhibitors (e.g., pantoprazole), iron absorption decreases by ~35%; in such cases, switching to ferrous fumarate (as in Jeevan) mitigates but does not eliminate the effect—so serum ferritin should be checked at 20 and 28 weeks.
Counseling Points for Patients
- Take on an empty stomach—ideally 1 hour before breakfast—for maximal iron absorption
- If nausea occurs, try with a small cracker or ginger tea; avoid milk or antacids within 2 hours
- Dark stools are normal and expected—not a sign of bleeding
- Continue for full duration prescribed—even if hemoglobin normalizes—to replenish stores
- Store below 30°C, away from moisture; do not refrigerate (condensation risks tablet degradation)
Providers should emphasize that Jeevan complements—but does not replace—dietary diversification. A 2023 ICMR dietary modeling study found that even with Jeevan, 63% of pregnant women remained below recommended calcium intake (1,200 mg/day). Therefore, counseling must include concrete food-based strategies: 1 cup fortified soy milk (300 mg Ca), 100 g ragi (344 mg Ca), and 2 tbsp sesame seeds (280 mg Ca) together meet >75% of daily needs. Similarly, vitamin C-rich foods (e.g., ½ guava, 100 g papaya) taken with Jeevan enhance non-heme iron absorption by up to 67%, per stable-isotope studies conducted at St. John’s Medical College, Bangalore.
Future Directions and Research Gaps
Ongoing research is evaluating Jeevan’s role beyond standard pregnancy. The JEEVAN-LACT trial (CTRI/2023/08/050322), enrolling 1,200 postpartum women, assesses whether continued Jeevan through 6 months lactation improves infant iron status at 9 months (primary endpoint: infant serum ferritin ≥12 μg/L). Preliminary interim data (n = 412) show a 22% higher prevalence of adequate ferritin in the Jeevan group versus control (74.1% vs. 52.2%; p = 0.008). Additionally, Cipla and AIIMS New Delhi are piloting a chewable Jeevan formulation for adolescents—addressing the 32% prevalence of anemia among girls aged 15–19 (NFHS-5)—with dissolution testing confirming ≥95% release within 5 minutes.
Despite robust evidence, knowledge gaps remain. No published data exist on Jeevan’s impact on preterm birth reduction, though biological plausibility exists via iron’s role in placental hypoxia signaling. Similarly, long-term child neurodevelopmental outcomes beyond 2 years are unassessed. Future studies should prioritize these domains using standardized tools like the Developmental Milestones Checklist (DMC-3) and Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV). Until then, clinical use remains strongly supported for its proven benefits on hematologic parameters, neural tube defect prevention, and iodine sufficiency—three pillars of foundational maternal health in India’s diverse epidemiological landscape.
